<DOC>
	<DOCNO>NCT03053206</DOCNO>
	<brief_summary>One-third one-half patient AML relapse general relapse AML patient poor prognosis . The treatment relapse AML consist induction chemotherapy follow Allogenic Stem Cell Transplant ( ASCT ) . However , present standard salvage chemotherapy regimen relapse AML , study show one regimen significantly superior . Anthracyclines , Fludarabine , Etoposide cytarabineare active agent AMLand use monotherapy combination refractory relapse AML patient . According previous study present CR rate different regimen range 50-70 % . A retrospective analysis ( unpublished ) conduct IRCH , AIIMS relapse AML patient treat ADE ( Cytarabine , Daunorubicin Etoposide ) chemotherapy show CR rate approximately 70 % . Therefore , plan study test efficacy toxicity ADE induction chemotherapy relapse AML patient prospective manner .</brief_summary>
	<brief_title>A Prospective , Interventional Study Assessing Response Cytarabine , Daunorubicin Etoposide ( ADE ) First Relapse Paediatric Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Either gender age â‰¤18 year initial diagnosis 2 . AML ( nonM3 ) patient first relapse ( medullary ) 1 . Primary refractory AML &amp; secondary AML 2 . More equal 2 relapse AML 3 . Symptomatic cardiac dysfunction ( CTCAE Grade 3 4 ) 4 . Active infection ( pneumonia etc . ) 5 . Any organ dysfunction ( CTCAE Grade 4 ) 6 . Patients willing consent study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>